How much does acalatinib cost after medical insurance reimbursement?

Acalabrutinib/Acalabrutinib, an original drug officially launched in China, provides a new treatment approach for adult patients with mantle cell lymphoma (MCL). Its unique pharmacological mechanism of action enables it to demonstrate significant therapeutic effects in clinical practice. However, for many patients, drug prices and medical insurance reimbursement are their biggest concerns.

First of all, as a drug for adult mantle cell lymphoma, acotinib needs to strictly follow the doctor's instructions during the treatment process and be used in accordance with the prescribed dosage and usage. At the same time, patients also need to undergo regular check-ups so that doctors can adjust treatment plans according to their condition.

In terms of medical insurance reimbursement, acotinib has been included in the medical insurance system, which is undoubtedly good news for patients. However, it should be noted that medical insurance reimbursement is not full reimbursement, but reimbursement based on a certain proportion. The specific reimbursement ratio varies from region to region, and patients need to understand the specific reimbursement situation according to the medical insurance policy of their location. In addition, due to the high price of acotinib, the common drug specifications are 100 mg, 8 pills and 7 plates. However, its price is not cheap, with each box selling for about more than 40,000 yuan. Even after medical insurance reimbursement, patients still need to bear a certain amount of financial pressure.

In general, the launch of acotinib provides patients with new treatment options, and the implementation of the medical insurance reimbursement policy also reduces patients' financial pressure. However, patients still need to follow medical instructions when using drugs and understand relevant reimbursement policies and price information in order to make the most reasonable treatment decisions. At the same time, we also look forward to more high-quality drugs being included in the medical insurance system in the future, bringing good news to more patients.